CDEK by Data4ThePeople
IndicationsMechanismsTrialsFDA ApprovalsAbout
Sign in Sign up
IndicationsMechanismsTrialsFDA ApprovalsAbout
← All indications

Bevacizumab

An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS.

Drugs by status

Phase 4 trials (3)

  • bevacizumab
  • ql1706
  • iparomlimab

Phase 3 trials (3)

  • icotinib
  • sodium chloride
  • hlx10

Phase 2 trials (19)

  • eribulin
  • fluorouracil
  • paclitaxel
  • nivolumab
  • leucovorin
  • niraparib
  • pemetrexed
  • trifluridine
  • capecitabine
  • adebrelimab
  • methotrexate
  • oxaliplatin
  • tipiracil
  • cisplatin
  • sintilimab
  • toripalimab
  • tislelizumab
  • Befotertinib
  • bms-986340

Other trials (1)

  • cadonilimab

CDEK

The Clinical Drug Experience Knowledgebase — tracking drugs, sponsoring organizations, and clinical trials from first-in-human testing through approval.

Browse

  • Drugs
  • Organizations
  • Trials

About

  • About CDEK
  • Glossary

Built and maintained by Data4ThePeople.

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED "AS IS", WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.